Description

This dataset describes a randomized clinical trial (Goldman et al., 1996) in which both survival and longitudinal data were collected to compare the efficacy and safety of two antiretroviral drugs, namely ddI (didanosine) and ddC (zalcitabine), in treating HIV-infected patients intolerant or failing zidovudine (AZT) therapy.

Usage

Format

A data.frame in the unbalanced format with 1405 longitudinal observations from 467 subjects. The columns are:

id

integer: number for patient identification.

time

numeric: time to death (or censoring).

death

integer: event indicator. Coded as 0 = right-censoring, and 1 = death.

obstime

numeric: measurement times for the repeated CD4 count measurements.

CD4

numeric: CD4 cell counts measured at obstime.

drug

factor: drug indicator. Coded as ddI = didanosine and ddC = zalcitabine.

gender

factor: gender indicator. Coded as male and female.

prevOI

factor: opportunistic infection indicator. Coded as AIDS = AIDS diagnosis at study entry, and noAIDS = no previous infection.

AZT

factor: AZT intolerance/failure indicator. Coded as intolerance or failure.

Source

Guo X, Carlin B. Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician. 2004; 58: 16-24

References

Goldman A, Carlin B, Crane L, Launer C, Korvick J, Deyton L, Abrams D. Response of CD4 and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996; 11: 161-169 URL: http://www.biostat.umn.edu/~brad/data.html.

See Also

heart.valve, epileptic, mental, liver.